Boston Scientific Vercise Deep Brain Stimulation System Receives CE Mark Approval

The Boston Scientific Corporation BSX Vercise Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions. Dystonia affects more than 500,000 people across Europe, including children and adults. It is the third most common movement disorder after Parkinson's disease and essential tremor.[1] Symptoms include involuntary muscle contractions, with twisting, repetitive movements or abnormal postures, which can be painful and debilitating.  The Vercise DBS System is the first system designed to selectively stimulate targeted areas of the brain in order to customize therapy and manage symptoms of Parkinson's disease.  This system now offers new hope for patients with dystonia.   The first implant of the Vercise DBS System for the treatment of dystonia was performed by a team from the Charité Campus Virchow-Klinikum (CVK), which included Prof. Dr. Andrea Kühn, Department of Neurology, and Dr. Gerd-Helge Schneider, Department of Functional Neurosurgery. "Historically, treatment of secondary dystonia has been challenging and efficacy was typically incomplete and partially limited by side effects.  The Vercise DBS system See full press release